vs
Side-by-side financial comparison of COMMVAULT SYSTEMS INC (CVLT) and Bio-Techne (TECH). Click either name above to swap in a different company.
COMMVAULT SYSTEMS INC is the larger business by last-quarter revenue ($311.7M vs $295.9M, roughly 1.1× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 4.7%, a 8.1% gap on every dollar of revenue. On growth, COMMVAULT SYSTEMS INC posted the faster year-over-year revenue change (13.3% vs -6.4%). Over the past eight quarters, COMMVAULT SYSTEMS INC's revenue compounded faster (17.8% CAGR vs 4.2%).
Commvault Systems, Inc. is an American publicly traded cybersecurity and data protection software company. Commvault's services are used for data security, as well as cloud and infrastructure management.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CVLT vs TECH — Head-to-Head
Income Statement — Q4 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $311.7M | $295.9M |
| Net Profit | $14.6M | $38.0M |
| Gross Margin | 81.4% | 64.6% |
| Operating Margin | 5.3% | 18.4% |
| Net Margin | 4.7% | 12.8% |
| Revenue YoY | 13.3% | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $0.34 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $311.7M | — | ||
| Q4 25 | $313.8M | $295.9M | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $282.0M | $317.0M | ||
| Q1 25 | $275.0M | $316.2M | ||
| Q4 24 | $262.6M | $297.0M | ||
| Q3 24 | $233.3M | $289.5M | ||
| Q2 24 | $224.7M | $306.1M |
| Q1 26 | $14.6M | — | ||
| Q4 25 | $17.8M | $38.0M | ||
| Q3 25 | $14.7M | — | ||
| Q2 25 | $23.5M | $-17.7M | ||
| Q1 25 | $31.0M | $22.6M | ||
| Q4 24 | $11.0M | $34.9M | ||
| Q3 24 | $15.6M | $33.6M | ||
| Q2 24 | $18.5M | $40.6M |
| Q1 26 | 81.4% | — | ||
| Q4 25 | 81.1% | 64.6% | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 82.0% | 62.7% | ||
| Q1 25 | 82.6% | 67.9% | ||
| Q4 24 | 81.5% | 65.3% | ||
| Q3 24 | 81.6% | 63.2% | ||
| Q2 24 | 82.3% | 66.4% |
| Q1 26 | 5.3% | — | ||
| Q4 25 | 6.3% | 18.4% | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.9% | -7.5% | ||
| Q1 25 | 9.7% | 12.2% | ||
| Q4 24 | 5.2% | 16.0% | ||
| Q3 24 | 6.4% | 13.8% | ||
| Q2 24 | 8.2% | 15.0% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | 5.7% | 12.8% | ||
| Q3 25 | 5.3% | — | ||
| Q2 25 | 8.3% | -5.6% | ||
| Q1 25 | 11.3% | 7.1% | ||
| Q4 24 | 4.2% | 11.7% | ||
| Q3 24 | 6.7% | 11.6% | ||
| Q2 24 | 8.2% | 13.3% |
| Q1 26 | $0.34 | — | ||
| Q4 25 | $0.40 | $0.24 | ||
| Q3 25 | $0.33 | — | ||
| Q2 25 | $0.52 | $-0.11 | ||
| Q1 25 | $0.68 | $0.14 | ||
| Q4 24 | $0.24 | $0.22 | ||
| Q3 24 | $0.35 | $0.21 | ||
| Q2 24 | $0.41 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $900.0M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $7.5M | $2.0B |
| Total Assets | $1.9B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $900.0M | — | ||
| Q4 25 | $1.0B | $172.9M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $363.2M | $162.2M | ||
| Q1 25 | $302.1M | $140.7M | ||
| Q4 24 | $243.6M | $177.5M | ||
| Q3 24 | $303.1M | $187.5M | ||
| Q2 24 | $287.9M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $7.5M | — | ||
| Q4 25 | $216.7M | $2.0B | ||
| Q3 25 | $210.5M | — | ||
| Q2 25 | $364.7M | $1.9B | ||
| Q1 25 | $325.1M | $2.0B | ||
| Q4 24 | $287.8M | $2.1B | ||
| Q3 24 | $277.8M | $2.1B | ||
| Q2 24 | $281.8M | $2.1B |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.0B | $2.5B | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.1B | $2.6B | ||
| Q4 24 | $1.0B | $2.7B | ||
| Q3 24 | $958.5M | $2.7B | ||
| Q2 24 | $934.9M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $132.2M | — |
| Free Cash FlowOCF − Capex | $131.8M | — |
| FCF MarginFCF / Revenue | 42.3% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 9.02× | — |
| TTM Free Cash FlowTrailing 4 quarters | $237.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $132.2M | — | ||
| Q4 25 | $4.0M | — | ||
| Q3 25 | $76.8M | — | ||
| Q2 25 | $31.7M | $98.2M | ||
| Q1 25 | $77.0M | $41.1M | ||
| Q4 24 | $30.1M | $84.3M | ||
| Q3 24 | $55.6M | $63.9M | ||
| Q2 24 | $44.7M | $75.5M |
| Q1 26 | $131.8M | — | ||
| Q4 25 | $1.9M | — | ||
| Q3 25 | $73.6M | — | ||
| Q2 25 | $29.8M | $93.3M | ||
| Q1 25 | $76.2M | $31.0M | ||
| Q4 24 | $29.9M | $77.5M | ||
| Q3 24 | $53.7M | $54.7M | ||
| Q2 24 | $43.8M | $57.5M |
| Q1 26 | 42.3% | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 26.6% | — | ||
| Q2 25 | 10.6% | 29.4% | ||
| Q1 25 | 27.7% | 9.8% | ||
| Q4 24 | 11.4% | 26.1% | ||
| Q3 24 | 23.0% | 18.9% | ||
| Q2 24 | 19.5% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.3% | 3.2% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.8% | 3.2% | ||
| Q2 24 | 0.4% | 5.9% |
| Q1 26 | 9.02× | — | ||
| Q4 25 | 0.23× | — | ||
| Q3 25 | 5.21× | — | ||
| Q2 25 | 1.35× | — | ||
| Q1 25 | 2.48× | 1.82× | ||
| Q4 24 | 2.74× | 2.42× | ||
| Q3 24 | 3.57× | 1.90× | ||
| Q2 24 | 2.41× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVLT
| Term-based license | $114.4M | 37% |
| Software-as-a-service | $93.1M | 30% |
| Customer support | $80.9M | 26% |
| Other | $13.1M | 4% |
| Perpetual license | $10.1M | 3% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
